Dean Edward Rummel, MPT in Annondale, NJ - Physical Therapist

Dean Edward Rummel, MPT is a Physical Therapist based in Annondale, New Jersey. Dean Edward Rummel is licensed to practice in New Jersey (license number QA08599) and his current practice location is 1465 St Highway 31, Annondale, New Jersey. He can be reached at his office (for appointments etc.) via phone at (908) 328-3300.

NPI number for Dean Edward Rummel is 1518926856 and his current mailing address is 4201 Bedford Dr, Bethlehem, Pennsylvania. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1518926856.

Contact Information

	Dean Edward Rummel, MPT
	1465 St Highway 31, Annondale, NJ 08801
	(908) 328-3300
	(908) 328-3268

Healthcare Provider's Profile

Full Name	Dean Edward Rummel
Gender	Male
Speciality	Physical Therapist
Location	1465 St Highway 31, Annondale, New Jersey
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1518926856
Provider Enumeration Date: 03/23/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dean Edward Rummel such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1518926856	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225100000X	Physical Therapist	QA08599 (New Jersey)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dean Edward Rummel is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dean Edward Rummel, MPT 4201 Bedford Dr, Bethlehem, PA 18020 Ph: (610) 861-3020	Dean Edward Rummel, MPT 1465 St Highway 31, Annondale, NJ 08801 Ph: (908) 328-3300

News Archive

Quanterix's ELISA precisely measures low abundance cytokines in Crohn's disease

Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn's disease.

Prior SARS-CoV-2 infection and risk of breakthrough infection following mRNA vaccination

The study, recently published in The Journal of the American Medical Association, deduced that previous SARS-CoV-2 infection is associated with a statistically significant reduced hazard of breakthrough infection among recipients of both the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines.

Global Fund has achieved impressive results, but more work remains

"This week I had the pleasure to host a preparatory meeting between donors of the Global Fund to Fight AIDS, Tuberculosis and Malaria," European Commissioner for Development Andris Piebalgs writes in the Huffington Post's "The Big Push" blog.

Rainbow Coral joins forces with BioHouston

Rainbow Coral Corp. positioned itself at the cutting edge of biotechnology innovation today by joining forces with BioHouston, Inc., one of the nation's preeminent drivers of life sciences research and commercialization.

Dean Edward Rummel, MPT - Physical Therapist in Annondale, NJ